免疫抑制剂是一类用于治疗自身免疫性疾病和器官移植排斥反应的药物,通过降低免疫系统的活性来减少炎症反应和组织损伤。
这类药物旨在提高机体的免疫力,主要用于改善免疫缺陷患者的状况或预防感染。
这类药物能够双向调节免疫反应,既可增强又可抑制免疫应答。
这些新型抗癌药物通过阻断癌细胞表面的PD-L1与T淋巴细胞上的PD-1受体之间的相互作用,从而解除对肿瘤杀伤性T细胞的抑制。
这是一种物理去除血液中有害物质的方法,在某些自身免疫性疾病中应用广泛。
这些药物在不同类型的疾病中发挥着重要作用,但同时也存在副作用风险,使用时需严格遵循医嘱。
中文名称 | 英文名称 | CAS号 | 化学式 | 结构式图片 |
---|---|---|---|---|
雷帕霉素 | sirolimus | 53123-88-9 | C51H79NO13 |
|
褪黑素 | 5-methoxy-N-acetyl-tryptamine | 73-31-4 | C13H16N2O2 |
|
咪唑立宾 | mizoribine | 50924-49-7 | C9H13N3O6 |
|
双醋瑞因 | diacetylrhein | 13739-02-1 | C19H12O8 |
|
依维莫司 | everolimus | 159351-69-6 | C53H83NO14 |
|
—— | (1R,9S,12S,15R,16Z,18R,19R,21R,23S,24E,26Z,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone | 159351-69-6 | C53H83NO14 |
|
—— | (1R,9S,12S,15R,16Z,18R,19R,21R,23S,24Z,26Z,28Z,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone | 159351-69-6 | C53H83NO14 |
|
—— | (1R,9S,12S,15R,16E,18R,19R,21R,23R,24Z,26E,28E,30S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone | 159351-69-6 | C53H83NO14 |
|
—— | Pharmakon1600-01504008 | 53123-88-9 | C51H79NO13 |
|
—— | (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone | 159351-69-6 | C53H83NO14 |
|
—— | 23,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone, 9,10,12,13,14,21,22,23,24, 25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-, [3S-[3R*[S* (1R*,3S*,4S*)],6S*,7E,9S*,10S*,12S*,14R*,15E,17E,19E,21R*, 23R*,26S*,27S*,34aR*]]- | 53123-88-9 | C51H79NO13 |
|
—— | 42-O-(2-hydroxyethyl)rapamycin) | 159351-69-6 | C53H83NO14 |
|
—— | Everolimus (RAD001) | 159351-69-6 | C53H83NO14 |
|
—— | (1S,9R,15R,16E,18R,19R,21S,23R,24E,26E,28E,30S,32R,35S)-1,18-dihydroxy-12-[(2S)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone | 159351-69-6 | C53H83NO14 |
|
—— | 4-acetamidobenzoic acid;9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one;1-(dimethylamino)propan-2-ol | 36703-88-5 | C24H34N6O9 |
|
—— | (1R,9S,12S,15R,16E,18R,19R,21R,23S,24Z,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone | 159351-69-6 | C53H83NO14 |
|
—— | AP-22594 | 53123-88-9 | C51H79NO13 |
|
—— | rapamycin | 53123-88-9 | C51H79NO13 |
|
—— | melatonin | 73-31-4 | C13H16N2O2 |
|
—— | bredinin | 50924-49-7 | C9H13N3O6 |
|
—— | mizoribine | 50924-49-7 | C9H13N3O6 |
|
—— | 1,18-Dihydroxy-12-[1-[4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone | 159351-69-6 | C53H83NO14 |
|